Inhibitex Inc., of Alpharetta, Ga., added Robert Schweiger as vice president of business development.
Kosan Biosciences Inc., of Hayward, Calif., added David Myles as executive director, chemistry.
KS Biomedix Holdings plc, of Guilford, UK, appointed Jim Carmichael, Mike James and Peter Stern to its scientific advisory board, and John Rennocks to its board.
Metabolex Inc., of Hayward, Calif., promoted Harold Van Wart to president and chief operating officer and Mark Bagnall to senior vice president.
Mimotopes Pty. Ltd., of Melbourne, Australia, appointed Andrew Milner managing director, Ronald Deane chairman and also named Thomas Sanders to its board.
NeoTherapeutics Inc., of Irvine, Calif., named Hagop Kantarjian, Enrico Mihich, Herbert Pinedo, Derek Raghavan, and Eric Rowinsky to its scientific advisory board.
Noxxon Pharma AG, of Berlin, appointed Michael Courtney chief scientific officer and Mathias Grote director of business development.
Oncolytics Biotech Inc., of Calgary, Alberta, appointed Wayne Schnarr vice president, corporate development.
Palatin Technologies Inc., of Princeton, N.J., appointed Robert Taber to its board.
Protein Polymer Technologies Inc., of San Diego, re-elected Richard Adelson, Patricia Cornell, Edward David, Philip Davis, Edward Hartnett, Kerry Kuhn, Paul Jones, Thomas Parmeter and George Walker to its board.
Response Biomedical Corp., of Vancouver, British Columbia, appointed Stephen Kahn to its scientific advisory board.
RHeoGene LLC, of Charlottesville, Va., appointed Aaron Shatkin, Michael Ashburner, Leroy Hood and Jeffrey Trent to its scientific advisory board.
Seattle Genetics Inc., of Bothell, Wash., appointed Douglas Williams to its board and Dan Longo to its scientific advisory board.
SignalGene Inc., of Montreal, appointed Ian Anderson to its board.
Vical Inc., of San Diego, appointed Alan Dow vice president and general counsel and re-elected Patrick Latterell, Gary Lyons and Dale Smith as directors.